The outcome of radical prostatectomy for patients with prostate cancer and acute urinary retention

被引：0

作者：

Fernandez A. ^{[1
]}

Pautler S.E. ^{[1
]}

机构：

[1] Division of Urology, Department of Surgery and Division of Surgical Oncology, Department of Oncology, University of Western Ontario, London, ON

来源：

Journal of Robotic Surgery | 2010年 / 4卷 / 3期

关键词：

Prostate Cancer; Erectile Dysfunction; Benign Prostatic Hyperplasia; Lower Urinary Tract Symptom; Acute Urinary Retention;

D O I：

10.1007/s11701-010-0209-8

中图分类号：

学科分类号：

摘要：

Benign prostatic hyperplasia (BPH) is the fourth most commonly diagnosed medical condition in older men. As a consequence, acute urinary retention can occur in patients with preoperative prostate cancer. Robot-assisted radical prostatectomy as a treatment modality for prostate cancer was designed to decrease operative morbidity and minimize long-term morbidity such as incontinence and erectile dysfunction. Three patients with prostate cancer coexisting with a BPH-related urinary retention managed with a clean intermittent catheterization (patient #1), and an indwelling Foley catheter (patients #2 and #3), were treated with a robot-assisted radical prostatectomy. After the procedure, the patients were able to void spontaneously, with good urine flow and reasonable bladder emptying. © 2010 Springer-Verlag London Ltd.

引用

页码：201 / 204

页数：3

共 20 条

[1]

Issa M.M., Fenter T.C., Black L., Et al., An assessment of the diagnosed prevalence of disease in men 50 years of age or older, Am J Manag Care, 12, SUPPL. 4, (2006)

[2]

Naslund M.J., Issa M.M., Grogg A.L., Et al., Clinical and economic outcomes in patients treated for enlarged prostate, Am J Manag Care, 12, SUPPL. 4, (2006)

[3]

McConell J.D., Bruskewitz R., Walsh P., Et al., The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia, N Engl J Med, 338, pp. 557-563, (1998)

[4]

Kaplan S.A., Update on the American Urological Association guidelines for the treatment of benign prostatic hyperplasia, Rev Urol, 8, SUPPL. 4, (2006)

[5]

Barkin J., Guimaraes M., Jacobi G., Et al., Alpha blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5 alpha reductase inhibitor dutasteride, Eur Urol, 44, pp. 461-466, (2003)

[6]

McConell J.D., Roehrborn C.G., Bautista O.M., Et al., The long term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia, N Engl J Med, 349, pp. 2387-2398, (2003)

[7]

Naslund M., Eaddy M.T., Hogue S.L., Kruep E.J., Shah M.B., Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery, Curr Med Res Opin, 25, 11, pp. 2663-2669, (2009)

[8]

Fitzpatrick J.M., Kirby R.S., Management of acute urinary retention, BJU Int, 97, SUPPL. 2, pp. 16-22, (2006)

[9]

Kaplan S.A., Wein A.J., Staskin D.R., Et al., Urinary retention and post-void residual urine in men: separating truth from tradition, J Urol, 180, pp. 47-54, (2008)

[10]

Selius B.A., Subedi R., Urinary retention in adults: diagnosis and initial management, Am Fam Physician, 77, pp. 643-650, (2008)

← 1 2 →